Base de dados : MEDLINE
Pesquisa : C15.604.816 [Categoria DeCS]
Referências encontradas : 812 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 82 ir para página                         

  1 / 812 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28293010
[Au] Autor:Hayashi T; Tachibana S; Nakao K; Tokitsu K; Morita T
[Ad] Endereço:Department of Chest Surgery, Hokusetsu General Hospital, Takatsuki, Japan.
[Ti] Título:[Thymic Hyperplasia with Carcinoembryonic Antigen Elevation;Report of a Case].
[So] Source:Kyobu Geka;70(3):219-221, 2017 Mar.
[Is] ISSN:0021-5252
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:A 64-year-old man was found to have serum carcinoembryonic antigen(CEA) elevation while undergoing an examination for recurrent gastroenteritis. His past medical history included gastroenteritis, rheumatoid arthritis, and diabetes. Blood testing revealed an increased CEA level of 153.00 ng/ml( normal ≤ 5.00 ng/ml). Chest computed tomography scan revealed an abnormal soft tissue shadow measuring 5.7 × 1.2 × 7 cm in the anterior mediastinum. The soft tissue shadow in the anterior mediastinum was the only abnormality found by whole-body examination. The possibility of a malignant tumor could not be ruled out, and the surgery was performed. Histopathological examination of the specimen confirmed thymic hyperplasia, and immunohistochemical staining detected CEA-positive cells. Serum CEA level normalized at three months after surgery and also 2 years postoperatively.
[Mh] Termos MeSH primário: Antígeno Carcinoembrionário/sangue
Hiperplasia do Timo/sangue
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carcinoembryonic Antigen)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE


  2 / 812 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28286113
[Au] Autor:Kohler S; Keil TOP; Hoffmann S; Swierzy M; Ismail M; Rückert JC; Alexander T; Meisel A
[Ad] Endereço:Department of Experimental Neurology, Charité, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany; Department of Neurology, Charité, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany; NeuroCure Clinical Research Center, Charité, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany. Electronic addr
[Ti] Título:CD4 FoxP3 T regulatory cell subsets in myasthenia gravis patients.
[So] Source:Clin Immunol;179:40-46, 2017 Jun.
[Is] ISSN:1521-7035
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although myasthenia gravis (MG) is a classic autoantibody-mediated disease, T cells are centrally involved in its pathogenesis. In recent years a number of studies have analyzed the role of CD4 FoxP3 regulatory T cells (T ) in the disease with contradictory results. Here, the generation of T was significantly reduced in thymoma as compared to thymic hyperplasia and normal thymus tissue (p=0.0002). In the peripheral blood, T subsets classified according to CD49d, HELIOS and CD45RA expression changed after thymectomy and in the long-term course of immunosuppression. Compared to healthy volunteers the frequency of CD45RA FoxP3 T was reduced in MG patients in general (p=0.037) and in particular in patients without immunosuppression (p=0.036). In our study, thymectomy and immunosuppressive treatment were associated with changes in T subpopulations. The reduced frequency of CD45RA FoxP3 T we observed in MG patients might play a role in MG pathogenesis.
[Mh] Termos MeSH primário: Miastenia Gravis/imunologia
Subpopulações de Linfócitos T/imunologia
Linfócitos T Reguladores/imunologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Imunossupressores/uso terapêutico
Masculino
Meia-Idade
Miastenia Gravis/tratamento farmacológico
Miastenia Gravis/cirurgia
Subpopulações de Linfócitos T/efeitos dos fármacos
Linfócitos T Reguladores/efeitos dos fármacos
Timectomia
Timoma/tratamento farmacológico
Timoma/imunologia
Timoma/cirurgia
Timo/patologia
Hiperplasia do Timo/tratamento farmacológico
Hiperplasia do Timo/imunologia
Hiperplasia do Timo/cirurgia
Neoplasias do Timo/tratamento farmacológico
Neoplasias do Timo/imunologia
Neoplasias do Timo/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170818
[Lr] Data última revisão:
170818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE


  3 / 812 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28183214
[Au] Autor:Delitala AP; Olita L; Piras C; Cosseddu R; Bagella G; Fanciulli G
[Ad] Endereço:1 Internal Medicine Unit, University Hospital of Sassari, Sassari, Italy.
[Ti] Título:Appearance of a thymic mass after treatment of Cushing's syndrome.
[So] Source:Asian Cardiovasc Thorac Ann;25(2):150-153, 2017 Feb.
[Is] ISSN:1816-5370
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A 23-year-old woman was referred to our center with hirsutism, acne, weight gain, weakness, and irregular menses. Laboratory tests revealed increased levels of cortisol and sex hormones, and reduced adrenocorticotropic hormone levels. The patient underwent a right adrenalectomy. Pathology of the resected right adrenal gland showed an adrenal carcinoma. Computed tomography 8 months after the surgery revealed a thymic mass that was not detected preoperatively. The frequency of rebound thymic hyperplasia after normalization of hypercortisolism is not known, but possibly as high as 40%. Physicians must be aware of this phenomenon to avoid unnecessary thoracic surgery.
[Mh] Termos MeSH primário: Neoplasias do Córtex Suprarrenal/cirurgia
Adrenalectomia
Carcinoma Adrenocortical/cirurgia
Síndrome de Cushing/cirurgia
Segunda Neoplasia Primária
Hiperplasia do Timo/diagnóstico
Neoplasias do Timo/diagnóstico
[Mh] Termos MeSH secundário: Neoplasias do Córtex Suprarrenal/complicações
Neoplasias do Córtex Suprarrenal/diagnóstico
Carcinoma Adrenocortical/complicações
Carcinoma Adrenocortical/diagnóstico
Biópsia
Síndrome de Cushing/diagnóstico
Síndrome de Cushing/etiologia
Diagnóstico Diferencial
Feminino
Seres Humanos
Valor Preditivo dos Testes
Hiperplasia do Timo/diagnóstico por imagem
Hiperplasia do Timo/patologia
Neoplasias do Timo/diagnóstico por imagem
Neoplasias do Timo/patologia
Fatores de Tempo
Tomografia Computadorizada por Raios X
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170309
[Lr] Data última revisão:
170309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE
[do] DOI:10.1177/0218492316686480


  4 / 812 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28100409
[Au] Autor:Nakahara K; Nakane S; Nakajima M; Yamashita S; Mori T; Ando Y
[Ad] Endereço:Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. Electronic address: 97056kn@gmail.com.
[Ti] Título:Effect of thymectomy for thymic atrophy in myasthenia gravis: A retrospective study on 93 patients.
[So] Source:J Neuroimmunol;305:182-185, 2017 Apr 15.
[Is] ISSN:1872-8421
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:To clarify the efficacy of thymectomy among myasthenia gravis (MG) patients with and without thymoma. We classified MG patients who underwent thymectomy into 3 groups, such as thymic atrophy group, thymic follicular hyperplasia (TFH) group and thymoma group. We compared the data of clinical features and postoperative prognosis at very short-term, short-term, and medium-term. The clinical course of MG patients with atrophic thymus after thymectomy was even better than those of TFH or thymoma, in this retrospective study. However, we found no significant differences in the comparison of mean dose of prednisolone between the 3 groups at each time point.
[Mh] Termos MeSH primário: Miastenia Gravis/cirurgia
Complicações Pós-Operatórias/fisiopatologia
Timectomia/efeitos adversos
Timo/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticorpos/sangue
Atrofia/etiologia
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Miastenia Gravis/sangue
Complicações Pós-Operatórias/patologia
Radioimunoensaio
Receptores Colinérgicos/imunologia
Estudos Retrospectivos
Timoma/cirurgia
Hiperplasia do Timo/cirurgia
Neoplasias do Timo/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); 0 (Receptors, Cholinergic)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170120
[St] Status:MEDLINE


  5 / 812 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27746267
[Au] Autor:Marchevsky AM; Walts AE
[Ad] Endereço:Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048. Electronic address: Alberto.Marchevsky@cshs.org.
[Ti] Título:PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
[So] Source:Hum Pathol;60:16-23, 2017 Feb.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The checkpoint protein programmed cell death ligand-1 protein (PD-L1) binds to its receptor (PD-1) activating the PD-L1/PD-1 pathway, an important therapeutic target. There is limited information regarding PD-L1 and PD-1 expression in thymic lesions. Sections from nonneoplastic thymi (n = 20), thymomas World Health Organization types A, AB, B1, B2, and B3 (n = 38) and thymic squamous cell carcinoma (n = 8) were stained for PD-L1 (clone SP142; Spring BioScience), PD-1 (MRQ22; Cell Marque), CD4 (clone SPO32; Cell Marque), and CD8 (JCB117; Ventana). Immunoreactivity for each antibody was classified as focal or diffuse and scored as follows: 0, negative; 1%-5%, 1+; 6%-20%, 2+; and >20%, 3+. The proportions of cases expressing PD-L1, PD-1, CD4, and C8 at score ≥1+ were compared by diagnosis, using χ statistics. PD-L1 was expressed in 90% of nonneoplastic thymi, 92% of thymomas, and 50% of carcinomas, with significantly higher scores (P < .01) in B2 and B3 thymomas and carcinomas than in AB and B1 thymomas; PD-L1 was diffuse in most B2 and B3 thymomas and focal in carcinomas. PD-1 was focally expressed, and mostly with scores 1+, in 55% of nonneoplastic thymi, 63% of thymomas, and 37.5% of carcinomas. CD4+ and CD8+ cells were diffusely distributed with scores 3+ in all lesions other than B3 thymomas and carcinomas. The latter showed CD4+ cells mostly at the interface between neoplastic cells and stroma. PD-L1 and PD-1 are not expressed in similar locations and cellular proportions in thymic lesions, raising a question as to whether the PD-L1/PD-1 pathway is an actionable therapeutic target in these lesions.
[Mh] Termos MeSH primário: Antígeno B7-H1/análise
Biomarcadores Tumorais/análise
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD8-Positivos/imunologia
Carcinoma de Células Escamosas/imunologia
Linfócitos do Interstício Tumoral/imunologia
Receptor de Morte Celular Programada 1/análise
Timoma/imunologia
Hiperplasia do Timo/imunologia
Neoplasias do Timo/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Biópsia
Linfócitos T CD4-Positivos/patologia
Linfócitos T CD8-Positivos/patologia
Carcinoma de Células Escamosas/patologia
Carcinoma de Células Escamosas/cirurgia
Criança
Pré-Escolar
Feminino
Seres Humanos
Imuno-Histoquímica
Lactente
Linfócitos do Interstício Tumoral/patologia
Masculino
Meia-Idade
Valor Preditivo dos Testes
Timoma/patologia
Timoma/cirurgia
Hiperplasia do Timo/patologia
Hiperplasia do Timo/cirurgia
Neoplasias do Timo/patologia
Neoplasias do Timo/cirurgia
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (B7-H1 Antigen); 0 (Biomarkers, Tumor); 0 (CD274 protein, human); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161018
[St] Status:MEDLINE


  6 / 812 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27364860
[Au] Autor:Chen CH; Hsiao CC; Chen YC; Ko SF; Huang SH; Huang SC; Hsieh KS; Sheen JM
[Ad] Endereço:Department of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
[Ti] Título:Rebound Thymic Hyperplasia after Chemotherapy in Children with Lymphoma.
[So] Source:Pediatr Neonatol;58(2):151-157, 2017 Apr.
[Is] ISSN:2212-1692
[Cp] País de publicação:Singapore
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Development of mediastinal masses after completion of chemotherapy in pediatric patients with malignant lymphoma is worrisome and challenging to clinicians. METHODS: We performed a retrospective review of 67 patients with lymphoma treated at our hospital from January 1, 2001 to June 1, 2013. Patients who received at least two chest computed tomography (CT) examinations after complete remission (CR) was achieved were further analyzed. Gallium-67 scans and positron emission tomography (PET) were recorded and compared between these patients. RESULTS: Sixty-two of 67 patients reached CR, of whom 31 (22 male, 9 female) were patients that received at least two chest CT examinations after CR. Rebound thymic hyperplasia (RTH) was diagnosed in 21/31 patients (67.7%), including 14/23 (60.9%) and seven out of eight (87.5%) with non-Hodgkin's lymphoma and Hodgkin's lymphoma, respectively. Ages ranged from 3 years to 18 years (median 10 years). Increased radioactivity uptake of the anterior mediastinum in gallium scans was found in nine out of 20 patients (45%) with thymic rebound. PET was performed in six out of 21 patients. Increased fluorodeoxyglucose (FDG)-avid uptake in the anterior mediastinum was observed in four of six patients (66.7%) by PET. One patient received thymectomy. No patients with RTH had lymphoma relapse within the median follow-up period (5 years). Relapse was statistically significantly different (p = 0.001) between patients with and without RTH. CONCLUSION: RTH developed in 67.7% of pediatric patients with lymphoma in CR after chemotherapy. The association of RTH development and lowered relapse rates has yet to be determined. Awareness of this phenomenon is important in the prevention of unnecessary surgical intervention or chemotherapy.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Linfoma/tratamento farmacológico
Hiperplasia do Timo/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Indução de Remissão
Estudos Retrospectivos
Taiwan/epidemiologia
Hiperplasia do Timo/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170609
[Lr] Data última revisão:
170609
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160702
[St] Status:MEDLINE


  7 / 812 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26585984
[Au] Autor:Vázquez-Roque FJ; Hernández-Oliver MO; Medrano Plana Y; Castillo Vitlloch A; Fuentes Herrera L; Rivero-Valerón D
[Ad] Endereço:Servicio de Cirugía Cardiovascular, Cardiocentro de Santa Clara, Santa Clara, Villa Clara, Cuba. Electronic address: javier@cardiovc.sld.cu.
[Ti] Título:Results of surgical treatment for juvenile myasthenia gravis.
[Ti] Título:Resultados del tratamiento quirúrgico en la miastenia gravis juvenil..
[So] Source:Neurologia;32(3):137-142, 2017 Apr.
[Is] ISSN:1578-1968
[Cp] País de publicação:Spain
[La] Idioma:eng; spa
[Ab] Resumo:INTRODUCTION: Radical or extended thymectomy is an effective treatment for myasthenia gravis in the adult population. There are few reports to demonstrate the effectiveness of this treatment in patients with juvenile myasthenia gravis. OBJECTIVE: The main objective of this study was to show that extended transsternal thymectomy is a valid option for treating this disease in paediatric patients. RESULTS: Twenty-three patients with juvenile myasthenia gravis underwent this surgical treatment in the period between April 2003 and April 2014; mean age was 12.13 years and the sample was predominantly female. The main indication for surgery, in 22 patients, was the generalised form of the disease (Osserman stage II) together with no response to 6 months of medical treatment. The histological diagnosis was thymic hyperplasia in 22 patients and thymoma in one patient. There were no deaths and no major complications in the postoperative period. After a mean follow-up period of 58.87 months, 22 patients are taking no medication or need less medication to manage myasthenic symptoms. CONCLUSIONS: Extended (radical) transsternal thymectomy is a safe and effective surgical treatment for juvenile myasthenia gravis.
[Mh] Termos MeSH primário: Miastenia Gravis/cirurgia
Timectomia/métodos
Hiperplasia do Timo/cirurgia
[Mh] Termos MeSH secundário: Criança
Feminino
Seguimentos
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151121
[St] Status:MEDLINE


  8 / 812 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27609276
[Au] Autor:Karni A; Asmail A; Drory VE; Kolb H; Kesler A
[Ad] Endereço:Neuroimmunology Clinic, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: arnonk@tlvmc.gov.il.
[Ti] Título:Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms.
[So] Source:J Neuroimmunol;298:58-62, 2016 09 15.
[Is] ISSN:1872-8421
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The reasons for the abrogation of self-immunological tolerance in patients with myasthenia gravis (MG) may be different between those with concomitant thymic hyperplasia or thymoma, and those with no evidence of thymic involvement. We conducted a retrospective observational case series study to investigate the epidemiology as well as the clinical, serologic, and electromyographic (EMG) characteristics of individuals diagnosed as having MG. We found that the average age at MG onset of patients with either thymic hyperplasia or thymoma was much younger (by ~20years) than that of MG patients without thymic involvement. Thymic hyperplasia was more common in females than males. There were no differences in the rates of ocular MG vs. generalized MG among those three study groups. There were also no group differences in the rates of neuromuscular junction disfunction, as observed on EMG or by the results of serology tests for acetyl choline receptor antibody. Interestingly, only patients without thymic involvement had other autoimmune diseases, and most of them were females. The patients with other coexisting autoimmune disease had a similar age at MG onset as the other patients with no thymic involvement. These results shed light on the impact of epidemiological and clinical factors that result from different mechanisms of self-immunological tolerance breakdown that occurs in MG.
[Mh] Termos MeSH primário: Miastenia Gravis
Tolerância a Antígenos Próprios/fisiologia
Timo/patologia
[Mh] Termos MeSH secundário: Adulto
Idade de Início
Idoso
Autoanticorpos/sangue
Eletromiografia
Feminino
Seres Humanos
Masculino
Meia-Idade
Miastenia Gravis/epidemiologia
Miastenia Gravis/imunologia
Miastenia Gravis/fisiopatologia
Receptores Colinérgicos/imunologia
Estudos Retrospectivos
Fatores Sexuais
Timoma/epidemiologia
Hiperplasia do Timo/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Receptors, Cholinergic)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160910
[St] Status:MEDLINE


  9 / 812 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27561976
[Au] Autor:Chabi ML; Revel MP
[Ad] Endereço:Département d'imagerie cardiovasculaire et de radiologie interventionnelle, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: marie-laure.chabi@psl.aphp.fr.
[Ti] Título:[How to differentiate a thymic hyperplasia from an anterior mediastinal tumor?]
[Ti] Título:Comment différentier une simple hyperplasie thymique d'une tumeur médiastinale antérieure ?.
[So] Source:Rev Pneumol Clin;72(5):326-328, 2016 Oct.
[Is] ISSN:0761-8417
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Neoplasias do Mediastino/diagnóstico por imagem
Hiperplasia do Timo/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Diagnóstico Diferencial
Feminino
Seres Humanos
Lúpus Eritematoso Sistêmico/complicações
Lúpus Eritematoso Sistêmico/diagnóstico por imagem
Imagem por Ressonância Magnética
Neoplasias do Mediastino/complicações
Mediastino/patologia
Tamanho do Órgão
Radiografia Torácica
Hiperplasia do Timo/complicações
Hiperplasia do Timo/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170501
[Lr] Data última revisão:
170501
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160827
[St] Status:MEDLINE


  10 / 812 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27465275
[Au] Autor:Tzankov A
[Ad] Endereço:Institut für Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Schweiz. alexandar.tzankov@usb.ch.
[Ti] Título:[Non-neoplastic lesions of the mediastinum].
[Ti] Título:Nichtneoplastische Läsionen des Mediastinums..
[So] Source:Pathologe;37(5):400-11, 2016 Sep.
[Is] ISSN:1432-1963
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:The mediastinum is a complex body region of limited space but containing numerous organs of different embryonic origins. A variety of lesions that are difficult to distinguish from each other can occur here. Non-neoplastic lesions of the mediastinum represent important differential diagnostic pitfalls to mediastinal tumors, clinically, radiologically and histopathologically. It is important to bear these lesions in mind and to adequately verify or exclude them before starting further differential diagnostic considerations on mediastinal neoplasms. The most common non-neoplastic lesions in this region include cysts and lymphadenopathies. Mediastinal cysts result from abnormal events in the branching of the tracheobronchial tree, the pharyngeal pouches, the primary intestines, the pleuropericardial membranes and the brain meninges or are complications of inflammatory and hydrostatic processes. The histogenesis of the lining epithelium and the cyst wall structure are decisive for the exact classification. The histopathologically most prevalent patterns of mediastinal lymphadenopathies are those accompanied by increased histiocytes and Castleman's disease. Sclerosis is a non-specific reaction pattern of the mediastinum and can be associated with many processes; therefore, when establishing the diagnosis of sclerosing mediastinitis, several differential diagnoses have to be excluded. Simple thymic hyperplasia can be accompanied by considerable increase in organ size with severe local symptoms, while follicular thymic hyperplasia is often associated with myasthenia gravis and represents the most common findings in non-thymoma thymectomy specimens.
[Mh] Termos MeSH primário: Cisto Mediastínico/diagnóstico
Doenças do Mediastino/diagnóstico
[Mh] Termos MeSH secundário: Coristoma/diagnóstico
Coristoma/patologia
Diagnóstico Diferencial
Seres Humanos
Linfadenopatia/diagnóstico
Linfadenopatia/patologia
Cisto Mediastínico/patologia
Doenças do Mediastino/patologia
Neoplasias do Mediastino/diagnóstico
Neoplasias do Mediastino/patologia
Mediastinite/diagnóstico
Mediastinite/patologia
Mediastino/patologia
Esclerose/diagnóstico
Esclerose/patologia
Hiperplasia do Timo/diagnóstico
Hiperplasia do Timo/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160729
[St] Status:MEDLINE
[do] DOI:10.1007/s00292-016-0197-1



página 1 de 82 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde